The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Haifa Kathrin Al-AliDuring the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Haifa Kathrin Al-Ali, University Hospital Halle (Saale), Halle, DE. We asked, When would you switch a patient with myelofibrosis from ruxolitinib?
When would you switch a patient with myelofibrosis from ruxolitinib?
To answer this question, Al-Ali suggests decisions on switching from ruxolitinib should be made on an individual basis and by considering the overall clinical picture of patients with relapsed/refractory or ruxolitinib-intolerant disease.
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?